NCT00555204

Brief Summary

The purpose of this study is to test if the investigational medication ABT-089 is a safe and effective treatment for Alzheimer's disease.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
337

participants targeted

Target at P75+ for phase_2

Geographic Reach
1 country

42 active sites

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 1, 2007

Completed
6 days until next milestone

First Submitted

Initial submission to the registry

November 7, 2007

Completed
1 day until next milestone

First Posted

Study publicly available on registry

November 8, 2007

Completed
1.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2009

Completed
Last Updated

August 23, 2011

Status Verified

August 1, 2011

Enrollment Period

1.6 years

First QC Date

November 7, 2007

Last Update Submit

August 19, 2011

Conditions

Keywords

mild to moderate Alzheimer's disease, memory, cognition, dementia

Outcome Measures

Primary Outcomes (1)

  • Safety and Tolerability

    Baseline to Final Evaluation

Secondary Outcomes (2)

  • Pharmacokinetics (how the body handles the study drug)

    Baseline to Final Evaluation

  • Pharmacodynamic (how the study drug affects cognitive functions such as thinking and memory)

    Baseline to Final Evaluation

Study Arms (7)

A

EXPERIMENTAL
Drug: ABT-089

B

EXPERIMENTAL
Drug: ABT-089

C

EXPERIMENTAL
Drug: ABT-089

D

EXPERIMENTAL
Drug: ABT-089

E

EXPERIMENTAL
Drug: ABT-089

F

EXPERIMENTAL
Drug: ABT-089

G

PLACEBO COMPARATOR
Drug: placebo

Interventions

10 mg - capsules once daily for 12 weeks

B

placebo - capsules once daily for 12 weeks

G

Eligibility Criteria

Age55 Years - 90 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patient has mild to moderate Alzheimer's disease
  • Patient has been receiving a stable dose of an acetylcholinesterase inhibitor
  • Patient has a MMSE score between 12 and 26
  • Patient has a MHIS score of less than or equal to 4
  • Females must be postmenopausal for at least two years or surgically sterile
  • Patient has an identified, reliable, caregiver who will support him/her to ensure compliance with treatment and will accompany them to each outpatient visit

You may not qualify if:

  • Patient is living in a nursing home
  • Patient has a history of any significant neurologic disease other than Alzheimer's disease
  • Patient has any uncontrolled medical illness
  • Patient uses non-prescribed drugs of abuse or has a history of drug or alcohol abuse/dependence

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (42)

Unknown Facility

Phoenix, Arizona, 85006, United States

Location

Unknown Facility

Sun City, Arizona, 85351, United States

Location

Unknown Facility

Fresno, California, 93720, United States

Location

Unknown Facility

San Diego, California, 92108, United States

Location

Unknown Facility

Santa Ana, California, 92705, United States

Location

Unknown Facility

Santa Monica, California, 90404, United States

Location

Unknown Facility

Hamden, Connecticut, 06518, United States

Location

Unknown Facility

New Haven, Connecticut, 06510, United States

Location

Unknown Facility

Brooksville, Florida, 34613, United States

Location

Unknown Facility

Delray Beach, Florida, 33445, United States

Location

Unknown Facility

Fort Myers, Florida, 33901, United States

Location

Unknown Facility

Hallendale, Florida, 33009, United States

Location

Unknown Facility

Hialeah, Florida, 33016, United States

Location

Unknown Facility

Largo, Florida, 33770, United States

Location

Unknown Facility

Miami, Florida, 33180, United States

Location

Unknown Facility

Palm Beach Gardens, Florida, 33418, United States

Location

Unknown Facility

Sunrise, Florida, 33351, United States

Location

Unknown Facility

Tampa, Florida, 33613, United States

Location

Unknown Facility

West Palm Beach, Florida, 33407, United States

Location

Unknown Facility

West Palm Beach, Florida, 33409, United States

Location

Unknown Facility

Indianapolis, Indiana, 46260, United States

Location

Unknown Facility

Paducah, Kentucky, 42003, United States

Location

Unknown Facility

Pittsfield, Massachusetts, 01201, United States

Location

Unknown Facility

Grand Rapids, Michigan, 49503, United States

Location

Unknown Facility

St Louis, Missouri, 63141, United States

Location

Unknown Facility

Long Branch, New Jersey, 07740, United States

Location

Unknown Facility

Nutley, New Jersey, 07110, United States

Location

Unknown Facility

Princeton, New Jersey, 08540, United States

Location

Unknown Facility

Ridgewood, New Jersey, 07450, United States

Location

Unknown Facility

Albany, New York, 12208, United States

Location

Unknown Facility

New York, New York, 10021, United States

Location

Unknown Facility

Staten Island, New York, 10312, United States

Location

Unknown Facility

The Bronx, New York, 10454, United States

Location

Unknown Facility

Hickory, North Carolina, 28601, United States

Location

Unknown Facility

Winston-Salem, North Carolina, 27104, United States

Location

Unknown Facility

Centerville, Ohio, 45459, United States

Location

Unknown Facility

Cleveland, Ohio, 44106, United States

Location

Unknown Facility

Jenkintown, Pennsylvania, 19046, United States

Location

Unknown Facility

Norristown, Pennsylvania, 19401, United States

Location

Unknown Facility

San Antonio, Texas, 78229, United States

Location

Unknown Facility

Wichita Falls, Texas, 76309, United States

Location

Unknown Facility

Bennington, Vermont, 05201, United States

Location

Related Publications (1)

  • Lenz RA, Pritchett YL, Berry SM, Llano DA, Han S, Berry DA, Sadowsky CH, Abi-Saab WM, Saltarelli MD. Adaptive, dose-finding phase 2 trial evaluating the safety and efficacy of ABT-089 in mild to moderate Alzheimer disease. Alzheimer Dis Assoc Disord. 2015 Jul-Sep;29(3):192-9. doi: 10.1097/WAD.0000000000000093.

MeSH Terms

Conditions

Alzheimer DiseaseDementia

Interventions

pozanicline

Condition Hierarchy (Ancestors)

Brain DiseasesCentral Nervous System DiseasesNervous System DiseasesTauopathiesNeurodegenerative DiseasesNeurocognitive DisordersMental Disorders

Study Officials

  • Robert Lenz, MD, PhD

    Abbott

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 7, 2007

First Posted

November 8, 2007

Study Start

November 1, 2007

Primary Completion

June 1, 2009

Last Updated

August 23, 2011

Record last verified: 2011-08

Locations